Immune checkpoint inhibitor for non-small cell lung cancer with comorbid interstitial pneumonia; a prudent stance required

We read with interest the article entitled ‘Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis’ by Duchemann B, et al. in the March issue of the European Journal of Cancer [1]. The authors reported their experience using immune checkpoint inhibitor (ICI) in six non-small cell lung cancer (NSCLC) patients with comorbid idiopathic pulmonary fibrosis (IPF), with a typical usual interstitial pneumonia (UIP) pattern in 4 patients and a probable UIP pattern without honeycomb lung on computed tomography (CT) in 2 patients.

Lascia un commento